Ross B. Fulton

951 total citations
33 papers, 684 citations indexed

About

Ross B. Fulton is a scholar working on Immunology, Oncology and Epidemiology. According to data from OpenAlex, Ross B. Fulton has authored 33 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Immunology, 12 papers in Oncology and 8 papers in Epidemiology. Recurrent topics in Ross B. Fulton's work include Immune Cell Function and Interaction (11 papers), Immunotherapy and Immune Responses (11 papers) and T-cell and B-cell Immunology (7 papers). Ross B. Fulton is often cited by papers focused on Immune Cell Function and Interaction (11 papers), Immunotherapy and Immune Responses (11 papers) and T-cell and B-cell Immunology (7 papers). Ross B. Fulton collaborates with scholars based in United States and Czechia. Ross B. Fulton's co-authors include Steven M. Varga, David K. Meyerholz, Stephen C. Jameson, Ananda W. Goldrath, Kristin A. Hogquist, J. Adam Best, Yan Xing, Sara E. Hamilton, Allison F. Christiaansen and John T. Harty and has published in prestigious journals such as Journal of Clinical Oncology, Nature Immunology and The Journal of Immunology.

In The Last Decade

Ross B. Fulton

31 papers receiving 675 citations

Peers

Countries citing papers authored by Ross B. Fulton

Since Specialization

Citations

This map shows the geographic impact of Ross B. Fulton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ross B. Fulton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ross B. Fulton more than expected).

Fields of papers citing papers by Ross B. Fulton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ross B. Fulton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ross B. Fulton. The network helps show where Ross B. Fulton may publish in the future.

Co-authorship network of co-authors of Ross B. Fulton

This figure shows the co-authorship network connecting the top 25 collaborators of Ross B. Fulton. A scholar is included among the top collaborators of Ross B. Fulton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ross B. Fulton. Ross B. Fulton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies 2022 ·Frontiers in Oncology ·Anissa Chan, (unknown), Xiaohong Qiu, Mark Uhlik, Ross B. Fulton, (unknown), Keith Gorden, Yumi Yokoyama, Michael E. Danielson, (unknown), (unknown), Jeremy R. Graff, Nandita Bose	15
2	CD8+ T cell self-tolerance permits responsiveness but limits tissue damage 2021 ·eLife ·(unknown), Kristina S. Burrack, Todd P. Knutson, Henrique Borges da Silva, Katharine E. Block, Stephen D. O’Flanagan, (unknown), Arthur A. Hurwitz, Ross B. Fulton, Kristin R. Renkema, Stephen C. Jameson	9
3	Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models 2019 ·Molecular Cancer Therapeutics ·Walid S. Kamoun, Anne‐Sophie Dugast, James Suchy, Stephanie Grabow, Ross B. Fulton, (unknown), Lia Luus, (unknown), Alexander Koshkaryev, Gang Sun, Vasileios Askoxylakis, Eric M. Tam, Zhaohua Huang, Daryl C. Drummond, Andrew J. Sawyer	15
4	Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers 2019 ·The Journal of Immunology ·Nandita Bose, (unknown), Xiaohong Qiu, (unknown), (unknown), Mark Uhlik, (unknown), (unknown), (unknown), (unknown), (unknown), Richard M. Walsh, Anissa Chan, Ross B. Fulton, Steven Leonardo, Kathryn Fraser, Keith Gorden, Mark Matson, Jeremy R. Graff, Richard D. Huhn	12
5	Abstract 3270: Mechanism of action of a novel agonist TNFR2 antibody that induces co-stimulation of T cells and promotes robust anti-tumor immunity 2019 ·Cancer Research ·Ross B. Fulton, (unknown), (unknown), Jennifer Richards, Christina S.F. Wong, Alexander Koshkaryev, Lia Luus, Yang Jiao, Lihui Xu, Violette Paragas, (unknown), Marco Muda, Eric M. Tam, Daryl C. Drummond, Andreas Raue	1
6	Abstract 555: A novel human TNFR2 antibody (MM-401) modulates T cell responses in anti-cancer immunity 2019 ·Cancer Research ·(unknown), (unknown), Violette Paragas, Sandeep Kumar, (unknown), (unknown), (unknown), Ross B. Fulton, (unknown), Jennifer Richards, Christina S.F. Wong, Alexander Koshkaryev, James Suchy, Stephanie Grabow, Marco Muda, Andreas Raue, Daryl C. Drummond, Eric M. Tam	6
7	Effect of imprime PGG on innate immune-activating pharmacodynamic changes in a phase I clinical study in healthy human volunteers. 2017 ·Journal of Clinical Oncology ·Nandita Bose, (unknown), (unknown), (unknown), Mark Matson, Xiaohong Qiu, (unknown), (unknown), (unknown), (unknown), Anissa Chan, Kathryn Fraser, Richard M. Walsh, (unknown), Steven Leonardo, Ross B. Fulton, Keith Gorden, Mark Uhlik, Jeremy R. Graff, Richard D. Huhn	1
8	Abstract B29: Innate immune modulation: The novel immunotherapeutic Imprime PGG triggers the anti-cancer immunity cycle in concert with tumor-targeting, anti-angiogenic and checkpoint inhibitor antibodies 2017 ·Cancer Immunology Research ·Nandita Bose, Keith Gorden, Anissa Chan, (unknown), (unknown), David Walsh, (unknown), Benjamin R. Harrison, (unknown), Kathryn Fraser, Ross B. Fulton, Steven Leonardo, Mark Uhlik, Jeremy R. Graff	2
9	Abstract LB-199: Imprime PGG modulates immunosuppressive myeloid components of the tumor microenvironment and drives enhanced antitumor efficacy in combination with checkpoint inhibitor therapies 2017 ·Cancer Research ·(unknown), Anissa Chan, Xiaohong Qiu, Kathryn Fraser, (unknown), (unknown), Richard M. Walsh, Steven Leonardo, Ross B. Fulton, (unknown), Mark Uhlik, Jeremy R. Graff, Nandita Bose	2
10	Abstract 1703: A novel tumor vaccine platform: direct conjugation of antigens to the β glucan PAMP Imprime PGG enhances antigen presentation and T cell priming 2017 ·Cancer Research ·(unknown), Ross B. Fulton, Steven Leonardo, Keith Gorden, Jeremy R. Graff, Michael E. Danielson	1
11	Abstract 2335: Imprime PGG triggers PD-L1 expression on tumor and myeloid cells and prevents tumor establishment in combination with αPD-L1 treatment in vivo 2016 ·Cancer Research ·Kathryn Fraser, Anissa Chan, Ross B. Fulton, Steven Leonardo, (unknown), Xiaohong Qiu, (unknown), (unknown), Keith Gordon, Jeremy R. Graff, Nandita Bose	6
12	Abstract A160: Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming these cells for enhanced ROS production and tumor cell cytotoxicity 2016 ·Cancer Immunology Research ·Steven Leonardo, Ross B. Fulton, (unknown), Keith Gorden, (unknown), (unknown), Anissa Chan, Jeremy R. Graff	5
13	Abstract LB-089: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy 2016 ·Cancer Research ·Ross B. Fulton, Steven Leonardo, (unknown), Kathryn Fraser, Anissa Chan, (unknown), Michael E. Danielson, Nandita Bose, Jeremy R. Graff, Keith Gorden	3
14	Abstract 5034: Imprime PGG decreases regulatory T cell suppression and enhances T cell proliferation and differentiation revealing additional mechanisms for its anti-tumor activity 2015 ·Cancer Research ·Steven Leonardo, Keith Gorden, Ross B. Fulton, (unknown)	7
15	The TCR's sensitivity to self peptide–MHC dictates the ability of naive CD8+ T cells to respond to foreign antigens 2014 ·Nature Immunology ·Ross B. Fulton, Sara E. Hamilton, Yan Xing, J. Adam Best, Ananda W. Goldrath, Kristin A. Hogquist, Stephen C. Jameson	156
16	Aged Mice Exhibit a Severely Diminished CD8 T Cell Response following Respiratory Syncytial Virus Infection 2013 ·Journal of Virology ·Ross B. Fulton, (unknown), Lecia L. Pewe, John T. Harty, Steven M. Varga	30
17	Not all naïve CD8 T cells are created equal 2011 ·Immunology and Cell Biology ·Stephen C. Jameson, Ross B. Fulton	3
18	Effects of Aging on the Adaptive Immune Response to Respiratory Virus Infections 2009 ·Aging Health ·Ross B. Fulton, Steven M. Varga	27
19	A Proteomics Approach to Cloning Fenestrin from the Nuclear Exchange Junction of Tetrahymena 2008 ·Journal of Eukaryotic Microbiology ·Eric S. Cole, Paul C. Anderson, Ross B. Fulton, (unknown), (unknown), (unknown), Douglas L. Chalker, Jerry E. Honts, Mary Welch, (unknown), (unknown), Douglas J. Beussman	28
20	Functional impairment of CD8 T cells following acute virus infections (43.32) 2007 ·The Journal of Immunology ·Ross B. Fulton, Steven M. Varga	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact